Dr. Maida's background includes undergraduate degrees in microbiology, finance, and operations management. She holds a Master's Degree in Neurobiology and Anatomy, and a Ph.D. in molecular neuroscience, both of which were earned at the University of Rochester School of Medicine and Dentistry, Rochester, N.Y. Prior to her return to medical school, Dr. Maida served as CFO for a privately held consulting firm involved in the development of shopping malls and other commercial properties throughout the United States. She established The Medingen Group, LLC to provide medical professionals with the means to incubate and transfer their privately held intellectual property (IP) into the marketplace. In recent years, the Medingen Group has expanded to provide scientific, medical and clinical Due Diligence for Academic Institutions, Medical Institutions and Financial Institutions. The Medingen Group has grown to now serve as a research and development incubator for academic/medical institutions as well as medical professionals.
The products in The Medingen Group portfolio, which span multiple medical and scientific disciplines, address the current and emerging health and medical challenges facing the population. Dr. Maida also maintains a Medical Research position at the University of Rochester School of Medicine and Dentistry in the Department of Neurobiology and Anatomy where her laboratory investigates the molecular processes involved in neuroinflammation related to neurodegenerative disease, radiation, and cancer.
In her roles as CEO of the Medingen Group and its affiliates, Medingen Services and Clerisy Corp., Dr. Maida is able to successfully merge the disciplines of business and molecular medicine for the purpose of evaluating, developing and commercializing IP that provide novel solutions for patient and consumer needs that have been identified by the medical community.
"Our goal is to commercialize safe and responsible products developed within the scientific and medical communities. Products that will expand the breadth of patient care, personal health maintenance and potentially lead to better health outcomes. The advantage of Medingen operations is that we provide a fully integrated approach to evaluating and developing products that address clearly defined needs identified by the medical community, and will result in ease of use, improved patient comfort, better patient compliance, optimized health outcomes and acceptance by the medical community. The mission of The Medingen Group and its affiliates is to create healthier futures for all adults through commercialization of valuable IP developed within the scientific, medical, and medical research communities that provide solutions which exceed the efficacy and safety of current treatment options.”